A landmark Supreme Court decision to limit the broad regulatory authority of federal agencies will increase pressure for Congress to [...] Read More »
Articles by : William Newton, Associate Editor/Senior Writer
Canonsburg, Penn.-based Viatris yesterday became the 37th drugmaker to restrict the shipment of 340B-priced drugs in the contract pharmacy setting. [...] Read More »
More Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect
Four major drug manufacturers announced they will fully or partially exempt covered entities in certain states from their 340B contract [...] Read More »
Five new manufacturer restrictions on wholly-owned pharmacies taking effect in July will be “disastrous” for certain health center pharmacy arrangements, [...] Read More »
Two community health centers urged a federal appeals court to reverse an earlier dismissal of their lawsuit alleging four major [...] Read More »
The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last
Read More »
A powerful brand-name drug industry trade organization has asked a federal district judge to block Maryland from enforcing the state’s [...] Read More »
Fourteen years after the Congressional deadline, the long-anticipated revision to the 340B Administrative Dispute Resolution (ADR) process officially took effect [...] Read More »
A U.S. senator introduced a bill to extend 340B eligibility to certain outpatient rural hospitals with emergency services, mirroring a [...] Read More »
A key argument in AstraZeneca’s lawsuit challenging Arkansas’ 340B contract pharmacy access law has already been rejected by a higher [...] Read More »